Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

FDA approves ocular antiinflammatory agent

March 11, 1998

Preliminary results reported from phase II trials of Vitrase

March 6, 1998

Improved vision in AMD patients in phase I/II using PhotoPoint technology

Feb. 25, 1998

Allergan's new antiglaucoma agents

Feb. 20, 1998

Genetic basis for RP described

Feb. 5, 1998

FDA issues approvable letter for BioLon

Feb. 4, 1998

Novo Nordisk discloses peripheral muscarinic cholinergic agonists

Jan. 13, 1998

NIH contemplates licensing ophthalmic technology to GenVec

Jan. 7, 1998

Alcon discloses new antiglaucoma agents in patent literature

Jan. 2, 1998

Medarex's secondary cataract product enters phase III

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...